<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>71</patient-age><report-id>PHHY2012JP105563</report-id><gender>female</gender><reactions><reaction>Interstitial pneumonia (grade 1)</reaction><reaction>Platelets decreased (Grade 2 )/ thrombocytopenia</reaction><reaction>Tumor enlargement</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>EVEROLIMUS</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>OCTREOTIDE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Pancreatic neuroendocrine tumour</indication></indications><patient-age>71</patient-age><outcomes/><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053155_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134143</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012JP105563</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-15</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012JP105563</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Kazuya</reportergivename>
			<reporterfamilyname>Suzuki</reporterfamilyname>
			<reporterorganization>Kushiro City General Hospital</reporterorganization>
			<reporterdepartment>Department of Gastroenterology</reporterdepartment>
			<reportercity>Hokkaido</reportercity>
			<reportercountry>JP</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
			<literaturereference>Kazuga S et al.,. Successful Everolimus Therapy in a Patient with Nonfunctional Pancreatic Neuroendocrine Tumour, After Unsuccessful CDDP+VP16 Therapy</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>71</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Metastases to liver</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Interstitial pneumonia (grade 1)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Interstitial pneumonia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Interstitial lung disease</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Platelets decreased (Grade 2 )/ thrombocytopenia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Platelets decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Platelet count decreased</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Tumor enlargement</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Malignant neoplasm progression</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Malignant neoplasm progression</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testname>Alpha 1 foetoprotein increased</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Computerised tomogram</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Computerised tomogram</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Computerised tomogram</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>EVEROLIMUS</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>10 mg, daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pancreatic neuroendocrine tumour</drugindication>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Interstitial lung disease</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Interstitial lung disease</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Malignant neoplasm progression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Malignant neoplasm progression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>EVEROLIMUS</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugstructuredosagenumb>5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>5 mg, daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Interstitial lung disease</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Interstitial lung disease</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Malignant neoplasm progression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Malignant neoplasm progression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>OCTREOTIDE</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>19-667</drugauthorizationnumb>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pancreatic neuroendocrine tumour</drugindication>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OCTREOTIDE ACETATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Interstitial lung disease</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Interstitial lung disease</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Malignant neoplasm progression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Malignant neoplasm progression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012JP105563, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>literature report received on 15 Nov 2012 and follow up received on 05 Dec 2012. In this article the authors reported a case effectively treated with <Semaphore x="558929" class="Medicine" value="everolimus" score="0.98" ID="232653">everolimus</Semaphore>, who was refractory to CDDP + <Semaphore x="555467" class="Medicine" value="Etoposide" score="0.49" ID="268016">etoposide </Semaphore>(VP16) <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment</Semaphore>; the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>was interrupted temporarily due to <Semaphore x="2065402" class="Disease or Finding" value="Interstitial Pneumonia" score="1.00" ID="C27006">interstitial pneumonia</Semaphore>, although readministration of the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>was possible. This case refers to 71-year old female patient. This patient was referred to the hospital for detailed <Semaphore x="2647708" class="Procedure" value="Tumor Examination" score="1.00" ID="C90479">examination of <Semaphore x="2369974" class="Disease or Finding" value="Pancreatic Neoplasm" score="1.00" ID="C3305">tumors </Semaphore></Semaphore>
    <Semaphore x="2603306" class="AnatomicStructure" value="Tail of the Pancreas" score="1.00" ID="C12271">of <Semaphore x="2603306" class="AnatomicStructure" value="Tail of the Pancreas" score="1.00" ID="C12271">tail of pancreas </Semaphore></Semaphore>and multiple <Semaphore x="2119807" class="AnatomicStructure" value="Liver" score="1.00" ID="C12392">liver </Semaphore><Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumors</Semaphore>. Although an <Semaphore x="2728832" class="MedDRA LLT" value="Alpha 1 foetoprotein increased" score="1.00" ID="10001781">increase in <Semaphore x="1472072" class="Procedure" value="Alpha-fetoprotein Measurement" score="1.00" ID="C74732">AFP </Semaphore></Semaphore>to 189.5n g/mL and NSE to 61 pg/mL was observed, <Semaphore x="1409018" class="Disease or Finding" value="Abnormality" score="1.00" ID="C9440">abnormalities </Semaphore>in <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore>levels were not observed. Contrast enhanced CT revealed hypervascular <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore>of 3 cm in size in <Semaphore x="2603306" class="AnatomicStructure" value="Tail of the Pancreas" score="1.00" ID="C12271">tail of pancreas </Semaphore>and multiple <Semaphore x="2119807" class="AnatomicStructure" value="Liver" score="1.00" ID="C12392">liver </Semaphore><Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumors</Semaphore>. <Semaphore x="1888007" class="Procedure" value="Endoscopic Ultrasound" score="1.00" ID="C46078">EUS </Semaphore>guided <Semaphore x="1937430" class="Procedure" value="Fine-Needle Aspiration" score="1.00" ID="C15361"><Semaphore x="2265594" class="Procedure" value="Needle Biopsy" score="1.00" ID="C15190"><Semaphore x="1937430" class="Procedure" value="Fine-Needle Aspiration" score="1.00" ID="C15361">fine <Semaphore x="2265594" class="Procedure" value="Needle Biopsy" score="1.00" ID="C15190">needle <Semaphore x="2764280" class="MedDRA LLT" value="Aspiration biopsy" score="1.00" ID="10056605">aspiration </Semaphore></Semaphore></Semaphore>
       <Semaphore x="2265594" class="Procedure" value="Needle Biopsy" score="1.00" ID="C15190">
        </Semaphore>
       <Semaphore x="1937430" class="Procedure" value="Fine-Needle Aspiration" score="1.00" ID="C15361">biopsy </Semaphore>
       <Semaphore x="2265594" class="Procedure" value="Needle Biopsy" score="1.00" ID="C15190">
        </Semaphore>
       </Semaphore>(<Semaphore x="1887986" class="Procedure" value="Endoscopic Ultrasound-Guided Fine-Needle Aspiration" score="1.00" ID="C67287"><Semaphore x="1888007" class="Procedure" value="Endoscopic Ultrasound" score="1.00" ID="C46078">EUS </Semaphore>FNA</Semaphore></Semaphore>) was performed to the pancreatic <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions</Semaphore>. Chromogranin A and <Semaphore x="2598058" class="Procedure" value="Synaptophysin and Hematoxylin Staining Method" score="1.00" ID="C28415">synaptophysin </Semaphore>were positive. The patient was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>with Stage IV pNET as <Semaphore x="2223048" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Liver" score="1.00" ID="C4758">liver <Semaphore x="3108419" class="MedDRA LLT" value="Metastasis" score="1.00" ID="10062194">metastases </Semaphore></Semaphore>were already observed, although <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumors </Semaphore>were assessed as <Semaphore x="1671920" class="Disease or Finding" value="Canadian Cardiovascular Society Grading Scale Class III" score="1.00" ID="C77267">Class III </Semaphore>by <Semaphore x="1834420" class="Procedure" value="Cytological Procedure" score="1.00" ID="C16490">cytology</Semaphore>. Two cycles of CDDP + VP16 <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">octreotide </Semaphore>were performed. CT revealed apparent <Semaphore x="3133749" class="MedDRA LLT" value="Neoplasm progression" score="1.00" ID="10061309"><Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore><Semaphore x="3133749" class="MedDRA LLT" value="Neoplasm progression" score="1.00" ID="10061309">enlargement</Semaphore>, and <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore></Semaphore><Semaphore x="1786370" class="Disease or Finding" value="Clinical Course of Disease" score="0.58" ID="C35461">response </Semaphore>was assessed as <Semaphore x="1786370" class="Disease or Finding" value="Clinical Course of Disease" score="0.58" ID="C35461">PD</Semaphore>. CDDP + VP16 <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>was discontinued. The patient received <Semaphore x="558929" class="Medicine" value="everolimus" score="0.98" ID="232653">everolimus </Semaphore>(manufacture unknown) for <Semaphore x="2369974" class="Disease or Finding" value="Pancreatic Neoplasm" score="1.00" ID="C3305">pancreatic neuroendocrine tumor</Semaphore>, on an unspecified date, at a dose of 10 mg daily, <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally</Semaphore>. The patient also received <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">octreotide </Semaphore>(manufacture unknown) for <Semaphore x="2369974" class="Disease or Finding" value="Pancreatic Neoplasm" score="1.00" ID="C3305">pancreatic neuroendocrine tumor</Semaphore>, on an unspecified date, at an unknown dose subcutaneously. CT at 1 month after the initiation of <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>revealed marked <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore>shrinkage. <Semaphore x="558929" class="Medicine" value="everolimus" score="0.98" ID="232653">Everolimus </Semaphore>was discontinued at 3 months and a half after the initiation of <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>due to <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">Grade </Semaphore>2 <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">thrombocytopenia</Semaphore>. <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">Octreotide </Semaphore>was also discontinued. <Semaphore x="1762050" class="AnatomicStructure" value="Chest" score="1.00" ID="C25389">Chest </Semaphore>CT confirmed <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">Grade </Semaphore>1 <Semaphore x="2065402" class="Disease or Finding" value="Interstitial Pneumonia" score="1.00" ID="C27006">interstitial pneumonia</Semaphore>. The reporter stated that they consulted the department of respiratory <Semaphore x="2210132" class="Procedure" value="Medication Administered at Birth" score="1.00" ID="C90603">medicine </Semaphore>and <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1081705" class="Medicine" value="prednisoLONE" score="0.74" ID="291320">prednisolone </Semaphore><Semaphore x="4644955591016449" class="Medicine - prednisoLONE - Dose" value="50 mg" score="0.49" ID="">50 mg </Semaphore><Semaphore x="4645419447484417" class="Medicine - prednisoLONE - Frequency" value="was" score="0.49" ID="">was </Semaphore>initiated. The symptom rapidly improved and thus <Semaphore x="1081705" class="Medicine" value="prednisoLONE" score="0.74" ID="291320">prednisolone </Semaphore>dose was decreased to 25 mg 1 week later, followed by a gradual dose reduction. CT at 1 month after the discontinuation of <Semaphore x="558929" class="Medicine" value="everolimus" score="0.98" ID="232653">everolimus </Semaphore>showed <Semaphore x="3133749" class="MedDRA LLT" value="Neoplasm progression" score="1.00" ID="10061309"><Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore>enlargement</Semaphore>, and administration of <Semaphore x="558929" class="Medicine" value="everolimus" score="0.98" ID="232653">everolimus </Semaphore><Semaphore x="2400457221734401" class="Medicine - everolimus - Dose" value="5 mg" score="0.49" ID="">5 mg </Semaphore><Semaphore x="2400517351276545" class="Medicine - everolimus - Frequency" value="was" score="0.49" ID="">was </Semaphore>resumed. The administration of <Semaphore x="941733" class="Medicine" value="Octreotide" score="0.93" ID="273660">octreotide </Semaphore>was also resumed. At the time of submission of this abstract, the patient was on <Semaphore x="558929" class="Medicine" value="everolimus" score="0.98" ID="232653">everolimus </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>without <Semaphore x="1786370" class="Disease or Finding" value="Clinical Course of Disease" score="0.58" ID="C35461">relapse </Semaphore>of <Semaphore x="2065402" class="Disease or Finding" value="Interstitial Pneumonia" score="1.00" ID="C27006">interstitial pneumonia</Semaphore>. The seriousness, <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>and causality of the events were not reported.Follow up of full <Semaphore x="1888420" class="Race" value="English" score="1.00" ID="C43853">English </Semaphore>translation received on 05 Dec 2012: Laboratory value<Semaphore x="2276159" class="Disease or Finding" value="Neoplasm by Special Category" score="0.58" ID="C7062"><Semaphore x="2158390" class="Disease or Finding" value="Malignant Neoplasm" score="1.00" ID="C9305">, event (<Semaphore x="2158390" class="Disease or Finding" value="Malignant Neoplasm" score="1.00" ID="C9305">Malignant neoplasm </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="3127610" class="MedDRA LLT" value="Neoplasm malignant" score="1.00" ID="10028997">progression</Semaphore>) and narrative were updated. Event verbatim was changed from "intestinal <Semaphore x="3076613" class="MedDRA LLT" value="Lung disorder" score="1.00" ID="10025082"><Semaphore x="2132044" class="AnatomicStructure" value="Lung Tissue" score="1.00" ID="C33024">lung </Semaphore>disease</Semaphore>" to "intestinal <Semaphore x="2411042" class="Disease or Finding" value="Pneumonia" score="1.00" ID="C3333">pneumonia</Semaphore>".</narrativeincludeclinical>
				<sendercomment>MR (Octreotide): Occurrence of interstitial pneumonia was confounded by the co-suspect everolimus intake. Thus the causality remained unassessable on product in question.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>